ASH

59th Annual Meeting and Exposition
Presentations
Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Follow-up Study from the MMRF Commpass Genomics Project

Result Type: Paper
Number: 325
Presenter: Alessandro Lagana
Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Genomics
Time and Location:
Sunday, December 10, 2017: 7:30 AM-9:00 AM
Bldg B, Lvl 3, B302-B303 (Georgia World Congress Center)

Integrative Analysis of the Genomic Landscape Underlying Multiple Myeloma at Diagnosis: An MMRF Commpass Analysis

Result Type: Paper
Number: 326
Presenter: Jonathan Keats
Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Genomics
Time and Location:
Sunday, December 10, 2017: 7:30 AM-9:00 AM
Bldg B, Lvl 3, B302-B303 (Georgia World Congress Center)

Comprehensive Identification of Fusion Transcripts in Multiple Myeloma: An MMRF Commpass Analysis

Result Type: Paper
Number: 61
Presenter: Sara Nasser
Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Transcriptional Regulatory Circuitries of Multiple Myeloma
Time and Location:
Saturday, December 9, 2017: 7:30 AM-9:00 AM
Bldg B, Lvl 4, B401-B402 (Georgia World Congress Center)

A Molecular Analysis of Cereblon-Related Immunomodulatory Drug Resistance in Commpass Multiple Myeloma Patients

Result Type: Paper
Number: 1754
Presenter: Sheri Skerget
Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
Time and Location:
Saturday, December 9, 2017: 5:30 PM-7:30 PM
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)
FGFR3 Mutations Are an Adverse Prognostic Factor in Patients with t(4;14)(p16;q32) Multiple Myeloma: An MMRF Commpass Analysis

Result Type: Paper
Number: 3027
Presenter: Brooks Benard
Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
Time and Location:
Sunday, December 10, 2017: 6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Comparative Analysis of Gene Expression Status to Predict Response to Initial Multiple Myeloma Treatment: Utility of the MMRF Commpass Database in Validating Historical Findings

Result Type: Paper
Number: 2178
Presenter: Aneel Paulus
Program: Oral and Poster Abstracts
Session: 904. Outcomes Research—Malignant Conditions: Poster I
Time and Location:
Saturday, December 9, 2017: 5:30 PM-7:30 PM
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Identifying High-Risk Phenotypes Using Three-Way Feature Interactions in Multiple Myeloma: An Analysis of Publically Available MMRF Commpass Study

Result Type: Paper
Number: 3034
Presenter: Caleb Stein
Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
Time and Location:
Sunday, December 10, 2017: 6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Result Type: Paper
Number: 267
Presenter: Michael Chapman
Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Mechanisms of Resistance and Prognosis
Time and Location:
Saturday, December 9, 2017: 4:00 PM-5:30 PM
Bldg B, Lvl 2, B211-B212 (Georgia World Congress Center)
Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients: Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

**Result Type:** Paper  
**Number:** 395  
**Presenter:** Daniel Auclair  
**Program:** Oral and Poster Abstracts  
**Session:** 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Genomics of The Pathogenesis and Progression of Multiple Myeloma  
**Time and Location:**  
Sunday, December 10, 2017: 9:30 AM-11:00 AM  
Bldg B, Lvl 3, B304-B305 (Georgia World Congress Center)

Biological and Prognostic Impact of Apobec-Induced Mutations in the Spectrum of Plasma Cell Dyscrasias

**Result Type:** Paper  
**Number:** 1771  
**Presenter:** Francesco Maura  
**Program:** Oral and Poster Abstracts  
**Session:** 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I  
**Time and Location:**  
Saturday, December 9, 2017: 5:30 PM-7:30 PM  
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma

**Result Type:** Paper  
**Number:** 393  
**Presenter:** Niamh Keane  
**Program:** Oral and Poster Abstracts  
**Session:** 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Genomics of The Pathogenesis and Progression of Multiple Myeloma  
**Time and Location:**  
Sunday, December 10, 2017: 9:30 AM-11:00 AM  
Bldg B, Lvl 3, B304-B305 (Georgia World Congress Center)

Multiple Myeloma Drivers of High Risk and Response to Stem Cell Transplantation Identified By Causal Machine Learning: Out-of-Cohort and Experimental Validation

**Result Type:** Paper  
**Number:** 3029  
**Presenter:** Leon Furchtgott  
**Program:** Oral and Poster Abstracts  
**Session:** 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II  
**Time and Location:**  
Sunday, December 10, 2017: 6:00 PM-8:00 PM  
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)
Adar-Mediated Aberrant a-to-I RNA Editing Is Driven By 1q Amplification and Contributes to Proteasome Inhibitor Resistance in Multiple Myeloma

**Result Type:** Paper  
**Number:** 268  
**Presenter:** Alessandro Lagana  
**Program:** Oral and Poster Abstracts  
**Session:** 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Mechanisms of Resistance and Prognosis  
**Time and Location:**  
Saturday, December 9, 2017: 4:00 PM-5:30 PM  
Bldg B, Lvl 2, B211-B212 (Georgia World Congress Center)

IKZF1/3 and CRL4CRBN E3 Ubiquitin Ligase Mutations Associate with IMiD Resistance in Relapsed Multiple Myeloma

**Result Type:** Paper  
**Number:** 270  
**Presenter:** Santiago Barrio Garcia  
**Program:** Oral and Poster Abstracts  
**Session:** 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Mechanisms of Resistance and Prognosis  
**Time and Location:**  
Saturday, December 9, 2017: 4:00 PM-5:30 PM  
Bldg B, Lvl 2, B211-B212 (Georgia World Congress Center)

ADAR1-Mediated GLI1 Editing Promotes Malignant Self-Renewal in Multiple Myeloma

**Result Type:** Paper  
**Number:** 1204  
**Presenter:** Leslie Crews  
**Program:** Oral and Poster Abstracts  
**Session:** 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster I  
**Time and Location:**  
Saturday, December 9, 2017: 5:30 PM-7:30 PM  
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Role of MAX As a Tumor Suppressor Driver Gene in Multiple Myeloma

**Result Type:** Paper  
**Number:** 4347  
**Presenter:** Santiago Barrio Garcia  
**Program:** Oral and Poster Abstracts  
**Session:** 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III  
**Time and Location:**  
Monday, December 11, 2017: 6:00 PM-8:00 PM  
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)
Identification of Novel Oncogenes and Tumor Suppressor Genes in Newly Diagnosed Multiple Myeloma

Result Type: Paper  
Number: 60  
Presenter: Brian Walker  
Program: Oral and Poster Abstracts  
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Transcriptional Regulatory Circuits of Multiple Myeloma  
Time and Location:  
Saturday, December 9, 2017: 7:30 AM-9:00 AM  
Bldg B, Lvl 4, B401-B402 (Georgia World Congress Center)

Computational Modeling of Protein Networks Predicts Treatment Outcomes in Multiple Myeloma (MM)

Result Type: Paper  
Number: 592  
Presenter: Hemant Murthy  
Program: Oral and Poster Abstracts  
Time and Location:  
Monday, December 11, 2017: 7:00 AM-8:30 AM  
Bldg B, Lvl 2, B211-B212 (Georgia World Congress Center)

Interleukin-6 Drives Multiple Myeloma Progression through Upregulating of CD147/Emmprin Expression and Its Sialylation

Result Type: Paper  
Number: 3037  
Presenter: Jinsong Hu  
Program: Oral and Poster Abstracts  
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II  
Time and Location:  
Sunday, December 10, 2017: 6:00 PM-8:00 PM  
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

A B-Cell like Phenotype Is Associated with Sensitivity to Venetoclax in Multiple Myeloma

Result Type: Paper  
Number: 3073  
Presenter: Vikas Gupta  
Program: Oral and Poster Abstracts  
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II  
Time and Location:  
Sunday, December 10, 2017: 6:00 PM-8:00 PM  
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)
Overexpression of EZH2 in Multiple Myeloma Is Associated with Poor Prognosis Regardless of Treatment with Novel Agents or High-Dose Chemotherapy

Result Type: Paper
Number: 4335
Presenter: Mark Schroeder
Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III
Time and Location:
Monday, December 11, 2017: 6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Transcriptional Plasticity Compensates for Ikaros and Aiolos Proteasomal Degradation and Mediates Resistance to IMiDs in Multiple Myeloma (MM)

Result Type: Paper
Number: 63
Presenter: Paola Neri
Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Transcriptional Regulatory Circuitries of Multiple Myeloma
Time and Location:
Saturday, December 9, 2017: 7:30 AM-9:00 AM
Bldg B, Lvl 4, B401-B402 (Georgia World Congress Center)

High-Risk Myeloma Is Demarcated By Immunoglobulin Lambda Light Chain Translocations

Result Type: Paper
Number: 1780
Presenter: Benjamin Barwick
Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
Time and Location:
Saturday, December 9, 2017: 5:30 PM-7:30 PM
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

PSMB9 Mediates Resistance to Bortezomib in Multiple Myeloma

Result Type: Paper
Number: 3836
Presenter: Aneel Paulus
Program: Oral and Poster Abstracts
Session: 605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster III
Time and Location:
Monday, December 11, 2017: 6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)
High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC

Result Type: Paper  
Number: 4533  
Presenter: Andrzej Jakubowiak  
Program: Oral and Poster Abstracts  
Session: 731. Clinical Autologous Transplantation: Results: Poster III  
Time and Location:  
Monday, December 11, 2017: 6:00 PM-8:00 PM  
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone

Result Type: Paper  
Number: 3133  
Presenter: Neha Korde  
Program: Oral and Poster Abstracts  
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II  
Time and Location:  
Sunday, December 10, 2017: 6:00 PM-8:00 PM  
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

“Direct to Drug” Screening As a Route to Individualized Therapy in Multiple Myeloma

Result Type: Paper  
Number: 3080  
Presenter: Nathalie Meurice  
Program: Oral and Poster Abstracts  
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II  
Time and Location:  
Sunday, December 10, 2017: 6:00 PM-8:00 PM  
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)
A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma in Persons of African Ancestry (African-American Multiple Myeloma Study (AAMMS)) Identifies Suggestive Risk Variants

Result Type: Paper
Number: 3058
Presenter: Wendy Cozen
Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
Time and Location:
Sunday, December 10, 2017: 6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Crowdsourcing a High-Risk Classifier for Multiple Myeloma Patients
Program: Oral and Poster Abstracts

Type: Oral
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Mechanisms of Resistance and Prognosis
Saturday, December 9, 2017: 4:00 PM
Bldg B, Lvl 2, B211-B212 (Georgia World Congress Center)
1. Dr. Gullu Gorgun, PhD, Oregon Health & Science University: Targeting Immune Suppressive MM Microenvironment

2. Dr. Enrico Milan, PhD, Fondazione Centro San Raffaele, Milan, Italy: Dissecting Multiple Myeloma addiction to p62: the unexpected role of FAM46C

3. Dr. Silvia Marino, PhD, Indiana University School of Medicine: XRK3, a Novel p62-ZZ Inhibitor, Reverses Osteoblast Suppression in Myeloma

4. Dr. Gregory Szeto, PhD University of Maryland Baltimore County: Predicting immunotherapy response in multiple myeloma by immune signatures

5. Dr. Qiang Wang, PhD, Cleveland Clinic Foundation: Role of MIF in Multiple Myeloma Drug Response